Xeolas Pharmaceuticals Ltd.

Dennis Mark McDaid

Maurice Joseph Anthony Clancy

Damien Patrick Flynn

The present disclosure relates to storage-stable proton pump inhibitor (PPI) systems comprising a therapeutically effective amount of a PPI or a pharmaceutically acceptable salt thereof, such as omeprazole or a pharmaceutically acceptable salt thereof, which are constituted with water prior to administration. The present disclosure also relates to oral pharmaceutical suspensions comprising water, a therapeutically effective amount of a PPI or a pharmaceutically acceptable salt thereof, such as omeprazole or a pharmaceutically acceptable salt thereof, and one or more buffering agents.

Growing community of inventors

Dublin, Ireland

Dennis Mark McDaid